Carisma Therapeutics Overview
- Year Founded
-
2016
- Status
-
Public
- Employees
-
68
- Stock Symbol
-
CARM
- Investments
-
1
- Share Price
-
$0.94
- (As of Friday Closing)
Carisma Therapeutics General Information
Description
CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.
Contact Information
Website
www.carismatx.comCorporate Office
- 3675 Market Street
- Suite 401
- Philadelphia, PA 19104
- United States
Corporate Office
- 3675 Market Street
- Suite 401
- Philadelphia, PA 19104
- United States
Carisma Therapeutics Timeline
Carisma Therapeutics Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.94 | $0.93 | $0.80 - $4.86 | $39.3M | 41.5M | 221K | -$1.74 |
Carisma Therapeutics Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | 14,122 | 26,855 | ||
| Revenue | 20,710 | 14,919 | 9,834 | 0 |
| EBITDA | (72,609) | (85,978) | (56,188) | (40,112) |
| Net Income | (72,501) | (86,879) | (61,226) | (40,784) |
| Total Assets | 59,339 | 89,554 | 72,153 | 35,449 |
| Total Debt | 8,168 | 3,123 | 40,164 | 2,632 |
Carisma Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Carisma Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Carisma Therapeutics Comparisons
Industry
Financing
Details
Carisma Therapeutics Competitors (45)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Kite Pharma | Formerly VC-backed | Santa Monica, CA | ||||
| NexImmune | Formerly VC-backed | Gaithersburg, MD | ||||
| ImmunoGen | Formerly VC-backed | Waltham, MA | ||||
| Gadeta | Formerly VC-backed | Utrecht, Netherlands | ||||
| Adimab | Venture Capital-Backed | Lebanon, NH |
Carisma Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Carisma Therapeutics Patents
Carisma Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2022407035-A1 | In vivo delivery to immune cells | Pending | 09-Dec-2021 | ||
| AU-2022215561-A1 | Self-polarizing immune cells | Pending | 02-Feb-2021 | ||
| CA-3206885-A1 | Self-polarizing immune cells | Pending | 02-Feb-2021 | ||
| EP-4288072-A1 | Self-polarizing immune cells | Pending | 02-Feb-2021 | ||
| US-20240299543-A1 | Self-polarizing immune cells | Pending | 02-Feb-2021 | A61K39/4614 |
Carisma Therapeutics Executive Team (15)
| Name | Title | Board Seat |
|---|---|---|
| Steven Kelly | Chief Executive Officer & Board Member | |
| Richard Morris | Chief Financial Officer, Finance | |
| Michael Klichinsky Ph.D | Chief Scientific Officer | |
| Elena Petrossian | Financial Controller & Senior Director | |
| Tom Wilton | Chief Business Officer |
Carisma Therapeutics Board Members (18)
| Name | Representing | Role | Since |
|---|---|---|---|
| Björn Odlander Ph.D | HealthCap | Board Member | |
| Briggs Morrison MD | Self | Board Member | |
| David Scadden MD | Self | Board Member | |
| Geeta Vemuri Ph.D | Agent Capital | Board Observer | |
| John Hohneker MD | Self | Board Member |
Carisma Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Carisma Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Carisma Therapeutics Acquisitions (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Sesen Bio | 07-Mar-2023 | Drug Discovery |
Carisma Therapeutics ESG
Risk Overview
Risk Rating
Updated February, 14, 2024
26.21 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 16,009
Rank
Percentile
Pharmaceuticals
Industry
of 909
Rank
Percentile
Biotechnology
Subindustry
of 404
Rank
Percentile
Carisma Therapeutics FAQs
-
When was Carisma Therapeutics founded?
Carisma Therapeutics was founded in 2016.
-
Who is the founder of Carisma Therapeutics?
Michael Klichinsky Ph.D and Saar Gill Ph.D are the founders of Carisma Therapeutics.
-
Who is the CEO of Carisma Therapeutics?
Steven Kelly is the CEO of Carisma Therapeutics.
-
Where is Carisma Therapeutics headquartered?
Carisma Therapeutics is headquartered in Philadelphia, PA.
-
What is the size of Carisma Therapeutics?
Carisma Therapeutics has 68 total employees.
-
What industry is Carisma Therapeutics in?
Carisma Therapeutics’s primary industry is Drug Discovery.
-
Is Carisma Therapeutics a private or public company?
Carisma Therapeutics is a Public company.
-
What is Carisma Therapeutics’s stock symbol?
The ticker symbol for Carisma Therapeutics is CARM.
-
What is the current stock price of Carisma Therapeutics?
As of 04-Oct-2024 the stock price of Carisma Therapeutics is $0.94.
-
What is the current market cap of Carisma Therapeutics?
The current market capitalization of Carisma Therapeutics is $39.3M.
-
What is Carisma Therapeutics’s current revenue?
The trailing twelve month revenue for Carisma Therapeutics is $20.7M.
-
Who are Carisma Therapeutics’s competitors?
Kite Pharma, NexImmune, ImmunoGen, Gadeta, and Adimab are some of the 45 competitors of Carisma Therapeutics.
-
What is Carisma Therapeutics’s annual earnings per share (EPS)?
Carisma Therapeutics’s EPS for 12 months was -$1.74.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
